Menu
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of pulmonary embolism and clot in transit in the right atrium.
Inari Medical Inc (NASDAQ: NARI ) shares gained on Thursday after the company reported Q2 revenues of $119.0 million, up 28.3% Y/Y, beating the consensus of $116.28 million . The increase over the prior year quarter was driven primarily by global commercial expansion, increased adoption of our procedures, and introduction of new products. The company reported Q2 EPS of $0.04, a turnaround from an EPS … Full story available on Benzinga.com
The company announced second-quarter earnings.
Inari Medical, Inc. (NASDAQ:NASDAQ:NARI) Q2 2023 Earnings Call Transcript August 2, 2023 4:30 PM ETCompany ParticipantsJohn Hsu - Vice President of Investor RelationsDrew Hykes - President…
Inari Medical press release (NARI): Q2 GAAP EPS of $0.04 beats by $0.16.Revenue of $119M (+28.4% Y/Y) beats by $2.28M.For the full year 2023, we are raising our revenue guidance to…
